A detailed history of Stifel Financial Corp transactions in Exelixis, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 16,006 shares of EXEL stock, worth $420,957. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,006
Previous 17,189 6.88%
Holding current value
$420,957
Previous $407,000 11.79%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$20.34 - $23.73 $24,062 - $28,072
-1,183 Reduced 6.88%
16,006 $359,000
Q1 2024

May 13, 2024

BUY
$20.17 - $23.93 $9,621 - $11,414
477 Added 2.85%
17,189 $407,000
Q4 2023

Feb 12, 2024

SELL
$19.25 - $24.13 $11,896 - $14,912
-618 Reduced 3.57%
16,712 $400,000
Q3 2023

Nov 13, 2023

BUY
$19.04 - $22.74 $9,634 - $11,506
506 Added 3.01%
17,330 $378,000
Q2 2023

Aug 14, 2023

BUY
$18.17 - $20.48 $305,692 - $344,555
16,824 New
16,824 $321,000
Q4 2022

Feb 13, 2023

SELL
$14.96 - $17.39 $850,580 - $988,743
-56,857 Reduced 46.9%
64,376 $1.03 Million
Q3 2022

Nov 14, 2022

SELL
$15.68 - $22.27 $314,995 - $447,382
-20,089 Reduced 14.22%
121,233 $1.9 Million
Q2 2022

Aug 15, 2022

SELL
$17.44 - $23.16 $55,773 - $74,065
-3,198 Reduced 2.21%
141,322 $2.94 Million
Q1 2022

May 13, 2022

BUY
$17.03 - $22.67 $8,446 - $11,244
496 Added 0.34%
144,520 $3.28 Million
Q4 2021

Feb 14, 2022

BUY
$15.84 - $21.88 $99,601 - $137,581
6,288 Added 4.57%
144,024 $2.63 Million
Q3 2021

Nov 15, 2021

BUY
$16.3 - $21.14 $51,654 - $66,992
3,169 Added 2.35%
137,736 $2.91 Million
Q2 2021

Aug 13, 2021

BUY
$17.95 - $25.56 $72,751 - $103,594
4,053 Added 3.11%
134,567 $2.45 Million
Q1 2021

May 14, 2021

BUY
$20.53 - $25.22 $295,981 - $363,596
14,417 Added 12.42%
130,514 $2.95 Million
Q4 2020

Feb 12, 2021

BUY
$18.39 - $24.8 $223,824 - $301,840
12,171 Added 11.71%
116,097 $2.33 Million
Q3 2020

Nov 16, 2020

BUY
$20.67 - $26.94 $106,781 - $139,172
5,166 Added 5.23%
103,926 $2.54 Million
Q2 2020

Aug 14, 2020

SELL
$16.46 - $27.42 $40,754 - $67,891
-2,476 Reduced 2.45%
98,760 $2.35 Million
Q1 2020

May 14, 2020

SELL
$14.46 - $21.8 $193,344 - $291,487
-13,371 Reduced 11.67%
101,236 $1.73 Million
Q4 2019

Feb 13, 2020

SELL
$15.15 - $18.89 $519,099 - $647,246
-34,264 Reduced 23.02%
114,607 $2.02 Million
Q3 2019

Nov 13, 2019

SELL
$17.68 - $22.65 $541,450 - $693,656
-30,625 Reduced 17.06%
148,871 $2.63 Million
Q2 2019

Aug 14, 2019

SELL
$18.93 - $24.75 $307,991 - $402,682
-16,270 Reduced 8.31%
179,496 $3.84 Million
Q1 2019

May 14, 2019

BUY
$19.6 - $24.76 $2.07 Million - $2.61 Million
105,481 Added 116.83%
195,766 $4.66 Million
Q4 2018

Feb 13, 2019

BUY
$13.65 - $21.8 $374,323 - $597,821
27,423 Added 43.62%
90,285 $1.77 Million
Q3 2018

Nov 13, 2018

SELL
$15.87 - $22.4 $295,578 - $417,200
-18,625 Reduced 22.86%
62,862 $1.11 Million
Q2 2018

Aug 14, 2018

BUY
$18.56 - $22.45 $253,418 - $306,532
13,654 Added 20.13%
81,487 $1.75 Million
Q1 2018

May 11, 2018

SELL
$22.15 - $31.89 $776,822 - $1.12 Million
-35,071 Reduced 34.08%
67,833 $1.5 Million
Q4 2017

Feb 14, 2018

BUY
$24.23 - $30.93 $725,203 - $925,734
29,930 Added 41.01%
102,904 $3.13 Million
Q3 2017

Nov 13, 2017

BUY
$23.35 - $29.24 $1.7 Million - $2.13 Million
72,974
72,974 $0

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $8.46B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.